Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H16NO |
Molecular Weight | 166.2401 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC[N+](C)(C)C1=CC(O)=CC=C1
InChI
InChIKey=VWLHWLSRQJQWRG-UHFFFAOYSA-O
InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
DescriptionSources: http://www.rxlist.com/enlon-drug.htm
Sources: http://www.rxlist.com/enlon-drug.htm
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Originator
Sources: https://www.google.com/patents/US2647924
Curator's Comment: reference retrieved from http://www.drugfuture.com/chemdata/edrophonium-chloride.html # Hoffmann La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
|||
Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397501 |
|||
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8109771 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
|||
Preventing | ENLON Approved UseEnlon (edrophonium injection) ® is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.
Enlon (edrophonium injection) ® is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. Launch Date1985 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
0.5 mg/kg single, intravenous dose: 0.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7224209/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
56.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
84.2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2169210/ |
1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: ATROPINE |
EDROPHONIUM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Train-of-four nerve stimulation in the management of prolonged neuromuscular blockade following succinylcholine. | 1975 Jan |
|
[Prognostic factors and outcome of thymectomy in 80 cases of myasthenia gravis]. | 2001 Apr |
|
Electrogastrography: a non-invasive measurement of gastric function. | 2001 Apr-Jun |
|
Edrophonium antagonism of cisatracurium-induced neuromuscular block: dose requirements in children and adults. | 2001 Aug |
|
Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. | 2001 Aug 1 |
|
Asystole induced by edrophonium following beta blockade. | 2001 Aug 28 |
|
Focal myopathy mimicking posterior interosseous nerve syndrome. | 2001 Jul |
|
[Voice disorders caused by neurological diseases]. | 2001 Jul 16-31 |
|
Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase? | 2001 Jun 26 |
|
Laryngeal myasthenia gravis: report of 40 cases. | 2001 Mar |
|
[Myasthenia gravis is improved temporarily at postburn period]. | 2001 May |
|
Medical therapies in myasthenia gravis. | 2001 May |
|
Interaction of edrophonium with muscarinic acetylcholine M2 and M3 receptors. | 2001 May |
|
[Giant-cell myocarditis without a symptom of heart failure seen in a patient with myasthenia gravis and concurrent Hashimoto's disease]. | 2001 Nov |
|
Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much? | 2001 Sep |
|
Autosomal recessive limb girdle myasthenia in two sisters. | 2002 Dec |
|
Noncardiac chest pain. | 2002 Jan |
|
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | 2003 |
|
Reversible and irreversible inhibitory activity of succinic and maleic acid derivatives on acetylcholinesterase. | 2003 Apr |
|
Clinical profile of myasthenia gravis in the Sultanate of Oman. | 2003 Jul |
|
[Response to thymectomy in patients with thymoma]. | 2003 Nov-Dec |
|
Prevalence of esophageal disorders in patients with recurrent chest pain. | 2004 |
|
Appearance of systemic lupus erythematosus in patients with myasthenia gravis following thymectomy: two case reports. | 2004 Feb |
|
[A case of transient left ventricular ballooning ("Takotsubo"-shaped cardiomyopathy) developed during plasmapheresis for treatment of myasthenic crisis]. | 2004 Mar |
|
Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. | 2004 Mar |
|
A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor. | 2004 Oct |
|
Evaluation of mechanisms of azinphos-methyl resistance in the codling moth Cydia pomonella (L.). | 2004 Oct |
|
'Dropped head sign' in myasthenia gravis. | 2004 Sep |
|
Sensory testing of the esophagus. | 2004 Sep |
|
Advances in the diagnosis of neuromuscular junction disorders. | 2005 Aug |
|
Edrophonium-induced right ventricular outflow tract tachycardia. | 2005 Jan |
|
Postinfectious myasthenia gravis: report of two children. | 2005 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.rxlist.com/enlon-drug.htm
Enlon (edrophonium injection) ® Test in the Differential Diagnosis of Myasthenia Gravis:1-8
Intravenous Dosage (Adults): A tuberculin syringe containing 1 mL (10 mg) of Enlon (edrophonium injection) ® is prepared with an intravenous needle, and 0.2 mL (2 mg) is injected intravenously within 15 to 30 seconds. The needle is left in situ. Only if no reaction occurs after 45 seconds is the remaining 0.8 mL (8 mg) injected. If a cholinergic reaction (muscarinic side effects, skeletal muscle fasciculations and increased muscle weakness) occurs after injection of 0.2 mL (2 mg), the test is discontinued and atropine sulfate, 0.4 mg to 0.5 mg, is administered intravenously. After one-half hour the test may be repeated.
Intramuscular Dosage (Adults): In adults with inaccessible veins, dosage for intramuscular injection is 1 mL (10 mg) of Enlon (edrophonium injection) ®. Subjects who demonstrate hyperreactivity to this injection (cholinergic reaction), should be retested after one-half hour with 0.2 mL (2mg) of Enlon (edrophonium injection) ® intramuscularly to rule out false-negative reactions.
For Use as a Curare Antagonist: Enlon (edrophonium injection) ® should be administered by intravenous injection in 1 mL (10 mg) doses given slowly over a period of 30 to 45 seconds so that the onset of cholinergic reaction can be detected. This dosage may be repeated whenever necessary. The maximal dose for any one patient should be 4 mL (40 mg). Because of its brief effect, Enlon (edrophonium injection) ® should not be given prior to the administration of curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine: it should be used at the time when its effect is needed. When given to counteract curare overdosage, the effect of each dose on the respiration should be carefully observed before it is repeated, and assisted ventilation should always be employed.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
||
|
NDF-RT |
N0000175723
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
||
|
NDF-RT |
N0000000177
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
251408
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
100000087722
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
1546421
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
ALTERNATIVE | |||
|
312-48-1
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
3202
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
3752
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
Edrophonium
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
Edrophonium
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
D004491
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
70FP3JLY7N
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
SUB01860MIG
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
DTXSID4046943
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
DB01010
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
988
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
70FP3JLY7N
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY | |||
|
C76137
Created by
admin on Fri Dec 15 15:55:27 GMT 2023 , Edited by admin on Fri Dec 15 15:55:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)